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Objective/Background: Patients with follicular lymphoma (FL) with early therapy failure (ETF)
within 2 years of frontline therapy have poor overall survival (OS). We recently reported the
results of autologous stem cell transplantation (ASCT) in patients from the Grupo Español de
Linfomas y Trasplantes de Médula Ósea (GELTAMO) registry treated with rituximab prior to
ASCT and with ETF after first-line immunochemotherapy, leading to 81% 5-year OS since ASCT.
We explored whether ASCT is also an effective option in the pre-rituximab era—that is, in
patients treated in induction and rescued only with chemotherapy.
Methods: ETF was defined as relapse/progression within 2 years of starting first-line therapy.
We identified two groups: the ETF cohort (n = 87) and the non-ETF cohort (n = 47 patients
receiving ASCT but not experiencing ETF following first-line therapy).
Results: There was a significant difference in 5-year progression-free survival between the ETF
and non-ETF cohorts (43% vs. 57%, respectively; p = .048). Nevertheless, in patients with ETF
with an interval from first relapse after primary treatment to ASCT of <1 year, no differences
were observed in 5-year progression-free survival (48% vs. 66%, respectively; p = .44) or in
5-year OS (69% vs. 77%, p = .4). Patients in the ETF cohort transplanted in complete remission
showed a plateau in the OS curves, at 56%, beyond 13.7 years of follow-up.
Conclusion: ASCT may be a curative option for ETF in patients who respond to rescue
chemotherapy, without the need for immunotherapy or other therapies, and should be consid-
ered as an early consolidation, especially in patients with difficult access to rituximab.
 2019 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an





















Follicular lymphoma (FL) is the most frequent subtype of
indolent non-Hodgkin lymphoma. Treatment improvements
in the past four decades have contributed to modifying
the natural history of FL, with median overall survival (OS)
approaching 20 years [1–3]. Nevertheless, FL remains lar-
gely incurable, relapses are common, and patients are often
chemorefractory and achieve less durable and lower-quality
responses after subsequent therapies [4]. Moreover, trans-
formation may occur, and many patients ultimately die
from the disease [5,6].
Prior to the approval of rituximab for the treatment of
non-Hodgkin lymphoma, combination chemotherapy and
prolonged therapy for patients with advanced FL requiring
treatment were shown to improve response rates and
extend first remission as compared with short-term alkylat-
ing agents alone, but with no improvement in OS [7]. The
addition of rituximab to conventional chemotherapy was a
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he need for immunotherapy, Hematol Odomized trials demonstrating the benefits, including better
OS, of first-line rituximab-containing chemotherapy [8–10].
Anti-CD20 maintenance therapy prolongs remission and
likely survival, and has become a standard of care after
first-line therapy [11]. However, for some patients, espe-
cially those in underdeveloped countries, access to ritux-
imab is difficult because of its high cost [12].
Several studies have shown that 15–20% of patients
with FL do not respond to first-line chemo-/
immunochemotherapy (refractoriness) or will experience
early therapy failure (ETF), defined as relapse or progres-
sion within 2 years of commencing first-line chemo/
immunochemotherapy [13–17]. The outcome for this sub-
group of high-risk FL patients is much worse than for those
responding well to first-line treatment, with reported 5-year
OS of approximately 50% versus 90% in the latter [15].
Several retrospective series have shown promising out-
comes in relapsed/refractory FL irrespective of previous
rituximab use [12–21]. No randomized study has thus far
evaluated the role of autologous stem cell transplantation
(ASCT) in relapsed FL in the rituximab era; however, in
patients naive to rituximab, the randomized European CUP
(cancer of unknown primary site) study showed an OS
advantage for ASCT over standard chemotherapy in relapsed
FL [22]. Nevertheless, there were too few patients in this
study who presented relapse within the first 2 years fromgous stem cell transplantation may be curative for patients with follicular lym-














































































Fig. 1 CONSORT diagram for follicular lymphoma patients in
the GELTAMO study. ASCT = autologous stem cell transplanta-
tion; CONSORT = Consolidated Standards of Reporting Trials;
CR = complete response; ETF = early therapy failure; FL = fol-
licular lymphoma; GELTAMO = Grupo Español de Linfomas y
Trasplantes de Médula Ósea; PR = partial response.
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specific outcome compared with those who experienced a
later relapse.
At present, there are no standard therapeutic options for
high-risk early failure FL, and considerable effort has been
placed on investigating novel therapies in this setting. We
recently published the results of ASCT in patients with FL
from the Grupo Español de Linfomas y Trasplantes de
Médula Ósea (GELTAMO) registry, treated with rituximab
prior to transplant and with ETF after first-line therapy
[23]. These patients had excellent survival, with 5-year OS
since ASCT > 80%. In the present study, we sought to analyze
whether ASCT is also an effective option in this high-risk
subgroup of FL patients prior to the use of rituximab, that
is, in patients treated in induction and rescued only with
chemotherapy.
Patients and methods
Study design and participants
The GELTAMO registry database includes 655 patients with
non-transformed FL who received ASCT between January
1, 1989 and December 31, 2007, at 44 centers in Spain. Of
this total, we identified 255 patients who underwent trans-
plantation in either second complete response (CR2) or sec-
ond partial response (PR2). Data on duration of response to
first-line immunochemotherapy were available for 202
patients; of these, a total of 134 patients (66%), who were
transplanted in either CR2 (n = 94) or PR2 (n = 40), were
naive to rituximab prior to ASCT. Therefore, the population
for this analysis comprised 134 non-transformed FL patients
with known duration of response to first-line therapy
(Fig. 1). Regarding histology, patients were classified per
the Working Formulation into follicular small cleaved cell,
follicular mixed small cleaved and large cell, or follicular
large cell, and according to the Revised European–Ameri-
can Classification of Lymphoid Neoplasms, as non-Hodgkin
lymphoma follicular Grade 1, 2, or 3 [24]. In this analysis,
ETF was defined as relapse/progression within 2 years of
starting first-ine chemotherapy. Patients in the GELTAMO
registry who underwent their first ASCT and experienced
relapse/progression within 2 years of starting first-line ther-
apy and underwent ASCT following achievement of a CR2 or
PR2 comprised the ETF cohort. Outcomes were compared
with those patients in the GELTAMO registry who received
their first ASCT in either CR2 or PR2, but who did not expe-
rience ETF following first-line therapy. All the patients
needed treatment at the time of initiation of salvage treat-
ment according to Groupe d’Etudes des Lymphomes Follicu-
laires (GELF) criteria [25].
Ethical approval
All procedures performed in studies involving human partic-
ipants were in accordance with the ethical standards of the
institutional and/or national research committee and with
the 1964 Helsinki Declaration and its later amendments or
comparable ethical standards. For this type of study, formal
consent is not required.Please cite this article as: A. Jiménez-Ubieto, C. Grande, D. Caballero et al., Autolo
phoma with early therapy failure without the need for immunotherapy, Hematol OResponse and disease status
According to GELTAMO guidelines, CR was defined as the
disappearance of all clinical evidence of disease, with nor-
malization of X-rays, computed tomography scans, and lab-
oratory values that had been abnormal prior to therapy; PR
was defined as 50% reduction in measurable disease for
1 month; and resistant/refractory disease was defined as
lymphoma that progressed during initial combination
chemotherapy or a response of less than PR to salvage ther-
apy. From 1999 onward, response criteria used were those
recommended internationally at the time of high-dose ther-
apy [26]. As the timing of ASCT in relapse/refractory FL is
not uniform across transplant centers, we compared out-
comes of ETF in FL patients who underwent, or not, an early
ASCT consolidation. Early ASCT was defined as transplanta-
tion performed within 1 year of ETF. The intent of this anal-
ysis was to evaluate the impact of early ASCT in FL patients
with ETF.
Statistical analysis
The primary study end point was OS. Progression-free sur-
vival (PFS) was defined as the time from ASCT to disease
relapse/progression or death from any cause. OS was ana-gous stem cell transplantation may be curative for patients with follicular lym-
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15 July 2019lyzed from the time of ASCT. Surviving patients were
censored at last follow-up. Patient-, disease-, and
transplantation-related factors were compared between
groups using the v2 test for categorical variables and the
Mann–Whitney U test for continuous variables. PFS and OS
were analyzed using the Kaplan–Meier method, and differ-
ences were assessed using the log-rank test. All p values
were two-sided, and p < .05 was considered statistically sig-
nificant. Univariate analyses of PFS and OS were conducted
for multiple patient-, disease-, and treatment-related fac-
tors. Statistically significant variables were included in mul-




Of the 134 patients included in the analysis, 87 experienced
ETF. Of these, 58 were transplanted in CR2 and 29 in PR2.
The non-ETF cohort comprised 47 patients who achieved
CR/PR and progressed more than 2 years after starting
first-line therapy. Of these, 36 were transplanted in CR2
and 11 in PR2. The time interval from first relapse after pri-
mary treatment to ASCT was 10 (range 4–56) months and 10
(range 4–37) months for the ETF and non-ETF cohorts,
respectively (p = .9). In the ETF and non-ETF groups, a total
of 78% (68/87) and 83% (39/47) of the patients, respec-
tively, received ASCT within the 1st year after treatment
failure (p = .5). The median follow-up from ASCT for the
134 patients was 13.4 years (range 9–97 months). The med-
ian time to progression within first-line therapy was 11
(range 0.1–23) months and 47 (range 25–114) months for
patients in the ETF and non-ETF cohorts, respectively
(p < .00001).
As first-line therapy, patients received either an
anthracycline-based (70%; 94/134) or a fludarabine-based
(2%; 3/134) regimen. Regarding rescue treatment, of the
106 patients with known data, 50% (53/106) received a
cisplatin-based regimen, 21% (22/106) a fludarabine-based
regimen, and 29% (31/106) an anthracycline-based regimen.
For transplantation, peripheral blood (PB) was used as the
progenitor cell source in 79% of patients (median number
of CD34+ cells infused 2.7  106/kg; range, 0.7–
15.4  106/kg). A total of 33/134 patients (25%) received
a total body irradiation-containing conditioning regimen.
The most commonly used conditioning regimen was car-
mustine, etoposide, cytarabine, and melphalan (BEAM;
46%; 61/134).
Patient/disease characteristics were well balanced
between the ETF and non-ETF cohorts. The only differences
were in the status according to the Eastern Cooperative
Oncology Group (ECOG) scale, with more patients having
ECOG  2 in the non-ETF group; and in the response to
frontline chemotherapy, with more patients reaching CR
in the non-ETF group (98% vs. 84%, p = .01; Table 1). In
the ETF cohort, there were no differences between the
group who received ASCT within 1 year (n = 68) ver-
sus > 1 year (n = 19) after first relapse, after primary
treatment.Please cite this article as: A. Jiménez-Ubieto, C. Grande, D. Caballero et al., Autolo
phoma with early therapy failure without the need for immunotherapy, Hematol OSurvival analysis and predictors of survival
A significant difference was found for PFS (p = .048)
between the ETF (n = 87) and non-ETF cohorts (n = 47), with
5-year PFS rates from the time of ASCT of 43% (95% confi-
dence interval [CI], 33–55%) and 57% (95% CI, 44–71%),
respectively (Fig. 2A). Nevertheless, in patients experienc-
ing ETF with an interval from first relapse after primary
treatment to ASCT of <1 year (n = 68), the 5-year PFS was
48% (95% CI, 36–60%), which was similar to that of the
non-ETF cohort (n = 19) (5-year PFS: 66%; 95% CI, 46–80%;
p = .44). No significant difference was found for OS (p = .4)
between the ETF and non-ETF cohorts, with 5-year OS rates
from the time of ASCT of 69% (95% CI, 59–79%) and 77% (95%
CI, 65–89%), respectively (Fig. 2B).
In the ETF cohort, multivariate analysis identified that
factors associated with a higher risk of mortality (i.e., infe-
rior OS) were male sex (hazard ratio [HR] = 2.46; 95% CI,
1.2–5.03; p = .01), older age (HR = 1.27; 95% CI, 1.05–10;
p = .0005), bone marrow infiltration at diagnosis
(HR = 2.24; 95% CI, 1.13–4.4; p = .02) and the use of bone
marrow as a stem cell source (HR = 5.7; 95% CI, 2.5–13;
p = .00002). Factors correlating with an inferior PFS were
male sex (HR = 2.36; 95% CI, 1.36–4.07; p = .002), older
age (HR = 1.97; 95% CI, 1.14–3.30; p = .01), and the use of
bone marrow as a stem cell source (HR = 2.58; 95% CI,
1.37–4.86; p = .003).
Response status at ASCT and survival in patients
with ETF
Patients with ETF transplanted in CR (n = 58) had a better OS
(HR = 1.95; 95% CI, 1.06–3.57; p = .03) but not a better PFS
(HR = 1.42; 95% CI, 0.84–2.42; p = .1) than those trans-
planted in PR (n = 29) (Fig. 3). Patients who underwent ASCT
in CR (n = 58) had a projected 5-year PFS and OS of 47% (95%
CI, 33–58%) and 74% (95% CI, 60–83%), respectively. In the
latter group, there was a plateau in the OS curves beyond
13.7 years of follow-up, at 56%. Patients who underwent
ASCT in PR (n = 29) had a projected 5-year PFS and OS of
36% (95% CI, 31–50%) and 57% (95% CI, 48–78%), respec-
tively (Fig. 3).
Causes of death and secondary malignancies
Among all 134 patients, 63 (47%) died: 49 after progression
of FL and 14 without presenting progression of the disease.
The causes of death of these 14 patients were infection (7
cases), secondary neoplasia (2 cases), cardiotixicity, hemor-
rhage, graft-versus-host disease (1 case each), and nonspec-
ified nonrelapsed mortality (2 cases). In the ETF and non-
ETF cohorts a total of 49% (n = 43) and 42% (n = 20) (p = .4)
of patients died. Nineteen patients (14.1%) developed a sec-
ondary malignancy (12 cases of solid tumors, including 2
skin cancers and 7 cases of myelodysplastic syndrome/acute
myelogenous leukemia) at a median of 9 years after ASCT.
Of these 19 patients, 11 have died, and the rest were still
alive at last follow-up. In the EFT and non-ETF cohorts, 14
patients (16%) and five patients (10.6%) developed sec-
ondary neoplasia (p = .4).gous stem cell transplantation may be curative for patients with follicular lym-
ncol Stem Cell Ther, https://doi.org/10.1016/j.hemonc.2019.06.001
Table 1 Main clinical features at diagnosis and treatment variables of early treatment failure and non-early treatment failure
groups.
Characteristics ETF Non-ETF pa
(n = 140) (n = 62)
Age at diagnosis, y
Median (range) 47 (25–73) 51 (22–70) .01
46, n/N (%) 65/140 (46) 25/62 (40)
>46, n/N (%) 75/140 (64) 37/62 (60)
Sex, n (%)
Male 72 (51) 32 (50) .6
Female 68 (49) 32 (50)
ECOG performance
status, n/N (%)b
0–1 113/132 (86) 59/61 (97) .02
2 19/132 (14) 2/61 (3)
Ann Arbor stage, n/N (%)
I–II 20/140 (14) 15/62 (24) .08
III–IV 120/140 (86) 47/62 (76)
B symptoms, n/N (%)
Absent 104/140 (75) 51/62 (82) .3
Present 36/140 (25) 11/62 (18)
Nodal sites, n/N (%)
4 50/73 (69) 26/37 (70) .9
>4 23/73 (31) 11/37 (30)
Bone marrow involvement, n/N (%)
Yes 74/133 (56) 29/59 (49) .4
No 59/133 (44) 30/59 (51)
Lactate dehydrogenase, n/N (%)
High 23/115 (20) 12/51 (24) .6
Normal 92/115 (80) 39/51 (76)
Tumor mass, cm, n/N (%)
<6 51/105 (49) 23/44 (52) .4
6 54/105 (51) 21/44 (48)
Hemoglobin level, g/dL, n/N (%)
12 48/59 (86) 23/29 (79) .4
<12 8/59 (14) 6/29 (21)
b2-Microglobulin level, n/N (%)c
Low 29/100 (29) 10/35 (21) .4
High 71/100 (71) 25/35 (71)
FLIPI score, n/N (%)
Intermediate-high 31/56 (55) 17/30 (57) .9
FLIPI 2 score, n/N (%)
Intermediate-high 41/57 (72) 23/31 (74) .9
Response to frontline therapy
CR2 118/140 (84) 60/62 (97) .008
PR  2 17/140 (12) 2/62 (3) .04
(continued on next page)
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Characteristics ETF Non-ETF pa
(n = 140) (n = 62)
Unknown 5/140 (4) 0
Median lines of therapy to
reach first response
1 111/140 (79) 57/62 (92) 0.02
1 29/140 (21) 5/62 (8)
Time from first relapse after
primary treatment
to ASCT, y, n/N (%)
1 103/140 (74) 52/62 (84) .1
>1 37/140 (26) 10/62 (16)
Disease status at ASCT, n/N (%)
CR2 95 (68) 50 (81) .005
PR  2 45 (32) 12 (19)
Anthracycline-based induction therapy
Yes 104/140 (74) 43/62 (69) .4
No 36/140 (26) 19/62 (31)
Receipt of rituximab prior
to HDT/ASCT, n/N (%)
Yes 52/140 (37) 16/62 (26) .1
No 88/140 (63) 46/62 (74)
TBI-based conditioning
regimen, n/N (%)
Yes 24/140 (17) 10/62 (16) .9
No 116/140 (83) 52/62 (84)
Use of PBPCs for ASCT, n/N (%)
Yes 119/140 (85) 55/62 (89) .5
No 21/140 (15) 7/62 (11)
Years of transplant
1989–1999 73/140 (52) 30/621 (48) .8
2000–2007 67/140 (48) 32/62 (52)
Note. In some categories, the % values may not sum to 100% because of rounding. ASCT = autologous stem cell transplantation;
CR = complete response; ECOG = Eastern Cooperative Oncology Group; ETF = early therapy failure; FLIPI = Follicular Lymphoma Inter-
national Prognostic Index; HDT = high-dose therapy; PBPCs = peripheral blood progenitor cells; PR = partial response; TBI = total body
irradiation.
a Comparison between transplantations performed after an early treatment failure or a non-early treatment failure.
b Performance status according to the ECOG scale: 0–1, low level of functional impairment; 2–4, high level of functional impairment.
c According to normal values of each laboratory.
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Patients with FL experiencing ETF following first-line
chemotherapy/immunochemotherapy lack effective treat-
ments and ETF has been recently validated as a prognostic
marker of poor outcome [15,16,27,28]. Data from the Cen-
ter for International Blood and Marrow Transplant Research
and the National LymphoCare Study on 174 non-ASCT
patients and 175 ASCT patients who received a rituximab-
based chemotherapy as frontline treatment showed that
there were no differences in 5-year OS between the two
groups (60% vs. 67%, respectively, p = .16) [29]. However,
patients with FL with ETF receiving ASCT soon after treat-Please cite this article as: A. Jiménez-Ubieto, C. Grande, D. Caballero et al., Autolo
phoma with early therapy failure without the need for immunotherapy, Hematol Oment failure (1 year of ETF, n = 123) had a higher 5-year
OS than those without ASCT (73% vs. 60%) [29]. Our previous
report from the GELTAMO registry [23], including only
patients from the rituximab era, showed no significant dif-
ference in PFS (49% vs. 60%, p = .49) or in OS (81% vs. 83%,
p = .8) between patients in the ETF or non-ETF cohort. Addi-
tionally, patients with early ASCT, performed within 1 year
of ETF, showed similar PFS (49% vs. 66%, p = .4) and OS (86%
vs. 85%, p = .9) to those in the non-ETF group. Overall, these
results suggest that ASCT is an effective treatment option
for transplant-eligible patients with high-risk FL who experi-
ence ETF in the rituximab era. Nevertheless, it is not known
whether this favorable outcome is a consequence of ASCT
alone or is the result of a synergistic effect of ASCT plusgous stem cell transplantation may be curative for patients with follicular lym-









































Fig. 2 Kaplan–Meier curves. (A) Progression-free survival and (B) overall survival from the time of autologous stem cell
transplantation, according to whether patients had early therapy failure (n = 87; black line) or not (n = 47; gray line) after first-line
therapy. ASCT = autologous stem cell transplantation.
Fig. 3 Kaplan–Meier curves. (A) Progression-free survival and (B) Overall survival from the time of autologous stem cell
transplantation (ASCT) in patients presenting early therapy failure according to the status of response at the moment of ASCT:
second complete response (n = 58, black line) or second partial response (n = 29, gray line).
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15 July 2019rituximab. In the present study, we demonstrate in a large,
long-term follow-up group of rituximab-naive patients that
ASCT is also an effective treatment in this setting, reaching
a 5-year PFS and OS since the time of ASCT of 43% and 67%,
respectively. Interestingly, in patients experiencing ETF
with an interval from first relapse after primary treatment
to ASCT of <1 year, there were no differences in 5-year
PFS (48% vs. 66%, respectively, p = .44) between the two
cohorts, which was similar to that for patients who received
an ASCT with an interval from first relapse after primary
treatment to ASCT of <1 year but receiving rituximab prior
to transplant (5-year PFS 49%) [23]. A very recent study
has reported the results from patients with advanced FL
who received frontline treatment within the GLSG1996 or
GLSG2000 trials, and who presented with ETF [30]. Those
patients who received ASCT (n = 52) showed a significant
survival benefit with a 5-year second-line PFS versus no
transplant patients (n = 46) of 51% versus 19% (p < .0001)
and a 5-year second-line OS of 77% versus 59% (p = .031).
Of the 52 patients who received ASCT, only 10 had receivedPlease cite this article as: A. Jiménez-Ubieto, C. Grande, D. Caballero et al., Autolo
phoma with early therapy failure without the need for immunotherapy, Hematol Orituximab prior to ASCT [30]. Moreover, ASCT had a greater
impact on improved treatment outcome as compared with
second-line rituximab. Similar results have been reported
by Le Gouill et al. [20] for patients in the FL2000 study
who were in progression after first-line therapy with or
without addition of rituximab to chemotherapy and inter-
feron. The authors found a significant difference in 3-year
OS (92% vs. 63%, respectively; p = 0.0003) between patients
receiving ASCT and those who did not. This benefit was rel-
evant irrespective of frontline rituximab exposure. By con-
trast, Sebban et al. [31] reported a stronger impact of
rituximab compared with ASCT in patients in the GELF-86
and GELF-94 trials. Of the 364 patients included in these
two studies, 98 had been treated with ASCT, including 33
after rituximab-containing salvage regimen. The 33 patients
on combined treatment presented a 5-year survival after
relapse >90%, suggesting a possible synergism between the
two therapies. Our results on patients treated with the com-
bination of rituximab plus ASCT [23] were somewhat better
than those who received ASCT only (5-year PFS and OS ofgous stem cell transplantation may be curative for patients with follicular lym-








































































Table 2 Clinical practice points.
 Patients with follicular lymphoma (FL) who experience early therapy failure (ETF) within 2 years of frontline therapy have poor
overall survival (OS).
 For patients naive to rituximab, the randomized European CUP (cancer of unknown primary site) study showed an OS advantage
for ASCT compared with standard chemotherapy in relapsed FL. Nevertheless, there were too few patients who presented relapse
within the first 2 years from diagnosis, and no information was available about their specific outcome.
 Our previous study showed that FL patients from the GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea)
with ETF after first-line therapy immunochemotherapy who undergo ASCT have an excellent survival, with 5-year OS since
ASCT greater than 80%.
 In the present study, we found that ASCT is also an effective option in ETF FL patients prior to the use of rituximab, leading to
a 5-year PFS and OS of 43% and 69%, respectively.
 Patients experiencing ETF with an interval from first relapse after primary treatment to ASCT of < 1 year have similar 5-year
PFS to the non-EFT cohort (48% vs. 66%, respectively; p = .44). No differences were found when these patients were compared
with rituximab-exposed patients who received ASCT with an interval from first relapse after primary treatment to ASCT of
<1 year (5-year PFS, 49%).
 These findings suggest that ASCT can be a curative option in ETF FL patients who respond to rescue treatments without the need
of rituximab, above all in patients experiencing ETF with an interval from first relapse after primary treatment to ASCT of <1 year.
Early ASCT could be a promising option in patients with difficult access to rituximab.
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15 July 201949% vs. 43% and 81% vs. 69%, respectively). However, the
differences disappeared when we analyzed exclusively
patients experiencing ETF with an interval from first relapse
after primary treatment to ASCT of <1 year (5-year PFS 49%
vs. 48%, respectively), suggesting that the possible synergis-
tic effect of rituximab plus ASCT is not as relevant if ASCT is
offered soon in the course of the disease.
In the present analysis, the time from first relapse after
primary treatment to ASCT was 10 months in both the ETF
and non-ETF cohorts, with both receiving mostly
anthracycline-containing induction regimens. The only rele-
vant difference between the two groups was the ECOG
score, with more patients having a performance status
according to the ECOG scale 2 in the non-ETF cohort,
and the response status to first-line therapy (significantly
better in the non-ETF group). There were no differences
in terms of age, status of disease at ASCT, or other
already-known prognostic factors in FL. The survival benefit
of PB over bone marrow as a stem cell source has been
observed in most of the settings, likely because PB is asso-
ciated with a reduction in the number of platelet transfu-
sions and with the time to platelet and neutrophil
recovery [32,33]. Male sex and older age have recently been
demonstrated as adverse prognostic factors both in the set-
ting of autologous transplantation [25] and in rituximab-
treated patients [11].
Overall, our results suggest that, whereas some patients
might benefit from more aggressive therapies, such as allo-
genic stem cell transplantations, or novel drugs, such as
immunomodulatory agents [34], monoclonal antibodies
[35], phosphoinositide 3-kinase inhibitors [36], or even the
application of bispecific T-cell engagers [37] and chimeric
antigen receptor T cells [38], there are a considerable num-
ber of patients in this high-risk ETF subgroup that can be
cured with ASCT, even in the absence of rituximab (Table 2).
This is a hopeful option, especially in patients with difficult
access to rituximab, as is the case in many underdeveloped
countries.
Our study has several limitations, including its retrospec-
tive design, the antiquity of the data, and the absence of a
cohort of non-ASCT patients. Nonetheless, we believe thePlease cite this article as: A. Jiménez-Ubieto, C. Grande, D. Caballero et al., Autolo
phoma with early therapy failure without the need for immunotherapy, Hematol Ofindings are valuable, owing to the very long follow-up and
the absence of standard therapeutic options for high-risk
early failure FL.
Conclusions
Our results lead us to suggest that ASCT can be a curative
option in ETF FL patients who respond to rescue treatments,
without the need of rituximab. These results are more
favorable when ASCT is performed in patients experiencing
ETF with an interval from first relapse after primary treat-
ment to ASCT of <1 year. Thus, early ASCT could be a hope-
ful option in patients with difficult access to rituximab.Acknowledgments
The authors acknowledge the patients and their families, all
participating members of the GELTAMO study group, Angel
Cedillo for administrative support, and Dr. Kenneth
McCreath for English editorial assistance, which was funded
by the Foundation Research Institute at the Hospital Univer-
sitario 12 de Octubre, and complied with Good Publication
Practice 3 ethical guidelines (Battisti et al., Ann Intern
Med 2015; 163:461–4).
Declaration of Competing Interest
The authors have stated that they have no conflicts of
interest.
Authors’ contributions
JUA, GC, and LJJ were involved in the study conception and
design, provision of study materials or patients, collection
and assembly of data, data analysis and interpretation,
manuscript writing, and manuscript approval. SA, CD, and
LG-A were involved in provision of study materials or
patients, collection and assembly of data, manuscript writ-gous stem cell transplantation may be curative for patients with follicular lym-






































































































































Transplantation in ETF FL in pre-rituximab era 9
HEMONC 294 No. of Pages 10, Model 6+
15 July 2019ing, and manuscript approval. The remaining authors were
involved in data analysis and interpretation, and manuscript
review and approval.
References
[1] Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM,
et al. Improvements in observed and relative survival in
follicular grade 1–2 lymphoma during 4 decades: the Stanford
University experience. Blood 2013;122:981–7.
[2] Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess
M, et al. Improvement of overall and failure-free survival in
stage IV follicular lymphoma: 25 years of treatment experience
at the University of Texas M.D. Anderson Cancer Center. J Clin
Oncol 2006;24:1582–9.
[3] Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL,
Chrischilles E, Link BK. Improved survival of follicular lym-
phoma patients in the United States. J Clin Oncol
2005;23:5019–26.
[4] Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J,
et al. Patterns of survival in patients with recurrent follicular
lymphoma: a 20-year study from a single center. J Clin Oncol
1995;13:140–7.
[5] Montoto S, Fitzgibbon J. Transformation of indolent B-cell
lymphomas. J Clin Oncol 2011;29:1827–34.
[6] Alonso-Álvarez S, Magnano L, Alcoceba M, Andrade-Campos M,
Espinosa-Lara N, Rodrı́guez G, et al. Risk of, and survival
following, histological transformation in follicular lymphoma in
the rituximab era. A retrospective multicenter study by the
Spanish GELTAMO group. Br J Haematol 2017;178:699–708.
[7] Lister TA. High-dose therapy for follicular lymphoma revisited:
not if, but when? J Clin Oncol 2003;21:3894–6.
[8] Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A,
et al. Rituximab added to first-line mitoxantrone, chlorambu-
cil, and prednisolone chemotherapy followed by interferon
maintenance prolongs survival in patients with advanced
follicular lymphoma: an East German Study Group Hematology
and Oncology Study. J Clin Oncol 2017;25:1986–92.
[9] Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A,
Raposo JC, et al. Phase III study of R-CVP compared with
cyclophosphamide, vincristine, and prednisone alone in
patients with previously untreated advanced follicular lym-
phoma. J Clin Oncol 2008;26:4579–86.
[10] Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A,
Metzner B, et al. The addition of rituximab to a combination of
fludarabine, cyclophosphamide, mitoxantrone (FCM) signifi-
cantly increases the response rate and prolongs survival as
compared with FCM alone in patients with relapsed and
refractory follicular and mantle cell lymphomas: results of a
prospective randomized study of the German Low-Grade
Lymphoma Study Group. Blood 2004;104:3064–71.
[11] Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D,
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